Sign In
29 Mar 2016 15:11
PuriCore plc
("PuriCore" or the "Company")
Director Dealing
29 March 2016 - PuriCore plc (AIM: PURI), announces that, Alex Martin, Chief Executive Officer and Executive Director of the Company, today purchased ordinary shares of 10p each in the share capital of the Company ("Shares").
Name | Date purchased | Number of Shares purchased | Purchase price of Shares | Shareholding following the purchase | % of issued share capital |
Alex Martin | 29 March 2016 | 100,000 | 28p | 100,000 | 0.20% |
-Ends-
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
| |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | |||
| |||
FTI Consulting | +44 (0) 20 3727 1000 |
| |
Simon Conway / Mo Noonan / Victoria Foster Mitchell |
| ||
| |||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| |
Aubrey Powell / Jen Boorer / Tom Smale |
| ||
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies, based on its proprietary hypochlorous acid platform technology. The Company has initiated a drug development program based upon its proprietary technology and formulations at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including potential rare disease indications. Currently, the Company serves the Supermarket Retail sector and Wound Care market (as a medical device) utilizing different formulations. For more information, visit www.puricore.com.
Follow the stocks
